Tyra Biosciences
Developer of oral FGFR-targeted medicines for urothelial cancers and achondroplasia.
Something off on this page? Send us feedback.
Profile
Develops oral FGFR-targeted medicines for urothelial cancers, achondroplasia, liver cancer, and bile-duct cancer using an in-house structure-guided discovery platform. Dabogratinib anchors a wholly owned clinical pipeline, and the pre-commercial business relies on external capital while candidates move through trials and regulatory review.
Develops oral small-molecule medicines around fibroblast growth factor receptor biology for targeted cancers and genetically defined conditions. Its SNÅP platform combines iterative co-crystal structures, cell assays, and animal models to design for selectivity and resistance coverage. Lead candidate dabogratinib is in mid-stage trials for low-grade upper-tract urothelial carcinoma, intermediate-risk non-muscle-invasive bladder cancer, and pediatric achondroplasia.
Earlier programs include TYRA-430, in an early-stage trial for FGF19-positive hepatocellular carcinoma, and TYRA-200, in an early-stage trial for treatment-resistant FGFR2-driven intrahepatic cholangiocarcinoma. Clinical trials extend across U.S. and international sites, while development is headquartered in Carlsbad. The pipeline is wholly owned, but no product is approved and no revenue has been generated; operations depend on clinical results, regulatory approvals, and external financing.
Company facts
Key statistics
Year to date −6.7% · Average volume (30d) 549.1K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Jefferies | Reiterate | Buy | $42 | ||
| Apr 14, 2026 | Guggenheim | Target | $54 | |||
| Feb 17, 2026 | H.C. Wainwright | Target | $30 | $45 | ||
| Feb 13, 2026 | Wedbush | Reiterate | Outperform | $37 | $53 | |
| Feb 3, 2026 | Oppenheimer | Reiterate | Outperform | $36 | $50 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$0.65 | −$0.69 | −6.2% | — | — | — | −20.97% |
| May 13, 2026Q1 FY26 | −$0.60 | −$0.64 | −6.7% | — | — | — | +0.88% |
| Mar 2, 2026Q4 FY25 | −$0.54 | −$0.57 | −5.6% | — | — | — | +1.51% |
| Nov 5, 2025Q3 FY25 | −$0.50 | −$0.50 | 0.0% | — | — | — | −3.64% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | −$138.0K | $0 | |
| Operating income | −$31.9M | −$31.5M | −$32.9M | −$36.5M | −$42.0M | −$49.0M | |
| Net income | −$28.1M | −$28.1M | −$29.9M | −$33.8M | −$39.3M | −$45.6M | |
| Diluted EPS | −$0.47 | −$0.47 | −$0.50 | −$0.57 | −$0.64 | −$0.69 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $353.9M · Total debt $5.6M · Total assets $383.4M · Shareholders' equity $353.7M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 59.66M · Float 44.33M · 74.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.20M | 20.45% | 13F | Aug 14, 2026 |
| FMR LLC | 8.92M | 14.95% | 13F | Aug 13, 2026 |
| Jupiter Topco LLC | 4.35M | 7.30% | 13F | Aug 14, 2026 |
| Janus Henderson Group PLC | 3.89M | 7.20% | 13G | May 15, 2026 |
| Alta Partners Management Company, L.P. | 3.82M | 6.41% | 13F | Jul 22, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 25, 2026 | Gilla Kaplan | director | −14,295 | $36.97 |
| Feb 12, 2026 | Daniel Bensen | officer: Chief Discovery Officer | −8,000 | $32.87 |
| Jan 12, 2026 | Daniel Bensen | officer: Chief Discovery Officer | −8,000 | $28.52 |
| Dec 19, 2025 | Robert J. More | director | −10,000 | $25.00 |
| Dec 12, 2025 | Daniel Bensen | officer: Chief Discovery Officer | −8,000 | $22.64 |
Peers
- Johnson & Johnson
Only approved FGFR inhibitor for mUC; advancing intravesical erda in IR NMIBC
- BridgeBio Pharma
Oral FGFR3 inhibitor for achondroplasia; Phase 3 met primary endpoint Feb 2026
- BioMarin
Approved CNP analog Voxzogo for achondroplasia; advancing long-acting BMN 333
- Ascendis Pharma (ADR)
Weekly SC CNP therapy for pediatric achondroplasia; FDA-approved Feb 2026
- Incyte
Pioneer FGFR inhibitor maker with FDA-approved pemigatinib in FGFR2-driven CCA
- Eli Lilly
Global pharma with FGFR3-selective mUC inhibitor and approved HCC VEGFR2 mAb
- Relay Therapeutics
Originator of FGFR2-selective lirafugratinib, licensed to Elevar for CCA
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Tyra Biosciences | $24.94 | −0.22% | $1.49B | — | — | — | — |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| BridgeBio Pharma | $76.60 | +0.03% | $15.00B | — | — | 21.7 | +120.4% |
| BioMarin | $64.67 | +0.02% | $12.50B | 165.8 | 10.4 | 3.7 | +19.9% |
| Ascendis Pharma (ADR) | $247.91 | 0.00% | $15.40B | 18.7 | 31.9 | 12.6 | +108.2% |
| Incyte | $124.37 | −0.03% | $25.21B | 15.8 | 43.0 | 4.3 | +37.7% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Relay Therapeutics | $19.10 | +1.82% | $4.11B | — | — | 397.4 | −48.3% |
| Median | 31.1 | 28.7 | 12.6 | +37.7% |